Bristol-Myers Squibb Company today announced new 4-year results from the long-term extensions of the BENEFIT and BENEFIT-EXT clinical trials of NULOJIX® , the first selective T-cell costimulation blocker indicated for the prophylaxis of organ rejection in adult Epstein-Barr Virus seropositive patients receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil ...
